Schick Kelly has filed 22 insider transactions across 1 company since February 2024.
Most recent transaction: a option exercise of 20950 shares of C4 Therapeutics, Inc. ($CCCC) on February 14, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 14, 2026 | C4 Therapeutics, Inc. | $CCCC | Schick Kelly | Chief People Officer | M | Common Stock | 20950 | $0.00 | 307,150.0000 | 96,914,418 | 7.32% | 0.02% |
| Feb. 13, 2026 | C4 Therapeutics, Inc. | $CCCC | Schick Kelly | Chief People Officer | F | Common Stock | 1735 | $1.89 | 307,150.0000 | 96,914,418 | 0.56% | 0.00% |
| Feb. 13, 2026 | C4 Therapeutics, Inc. | $CCCC | Schick Kelly | Chief People Officer | M | Common Stock | 5000 | $0.00 | 308,885.0000 | 96,914,418 | 1.65% | 0.01% |
| Feb. 13, 2026 | C4 Therapeutics, Inc. | $CCCC | Schick Kelly | Chief People Officer | A | Common Stock | 200000 | $0.00 | 308,885.0000 | 96,914,418 | 183.68% | 0.21% |
| Feb. 14, 2026 | C4 Therapeutics, Inc. | $CCCC | Schick Kelly | Chief People Officer | F | Common Stock | 7269 | $1.89 | 299,881.0000 | 96,914,418 | 2.37% | 0.01% |
| Feb. 13, 2025 | C4 Therapeutics, Inc. | $CCCC | Schick Kelly | Chief People Officer | F | Common Stock | 1735 | $3.20 | 54,753.0000 | 0 | 3.07% | 0.00% |
| Feb. 14, 2025 | C4 Therapeutics, Inc. | $CCCC | Schick Kelly | Chief People Officer | A | Common Stock | 56500 | $0.00 | 111,253.0000 | 0 | 103.19% | 0.00% |
| Feb. 14, 2025 | C4 Therapeutics, Inc. | $CCCC | Schick Kelly | Chief People Officer | F | Common Stock | 2368 | $3.18 | 108,885.0000 | 0 | 2.13% | 0.00% |
| Feb. 14, 2025 | C4 Therapeutics, Inc. | $CCCC | Schick Kelly | Chief People Officer | A | Stock Option (Right to Buy) | 84700 | $0.00 | 84,700.0000 | 0 | 9999.99% | 0.00% |
| Nov. 7, 2024 | C4 Therapeutics, Inc. | $CCCC | Schick Kelly | Chief People Officer | M | Performance Restricted Stock Units | 3750 | $0.00 | 10,500.0000 | 0 | 26.32% | 0.00% |
| Nov. 7, 2024 | C4 Therapeutics, Inc. | $CCCC | Schick Kelly | Chief People Officer | M | Common Stock | 3750 | $0.00 | 57,590.0000 | 0 | 6.97% | 0.00% |
| Nov. 7, 2024 | C4 Therapeutics, Inc. | $CCCC | Schick Kelly | Chief People Officer | F | Common Stock | 1102 | $6.04 | 56,488.0000 | 0 | 1.91% | 0.00% |
| Sept. 16, 2024 | C4 Therapeutics, Inc. | $CCCC | Schick Kelly | Chief People Officer | M | Performance Restricted Stock Units | 2250 | $0.00 | 14,250.0000 | 0 | 13.64% | 0.00% |
| Sept. 16, 2024 | C4 Therapeutics, Inc. | $CCCC | Schick Kelly | Chief People Officer | F | Common Stock | 661 | $6.36 | 53,840.0000 | 0 | 1.21% | 0.00% |
| Sept. 16, 2024 | C4 Therapeutics, Inc. | $CCCC | Schick Kelly | Chief People Officer | M | Common Stock | 2250 | $0.00 | 54,501.0000 | 0 | 4.31% | 0.00% |
| March 7, 2024 | C4 Therapeutics, Inc. | $CCCC | Schick Kelly | Chief People Officer | D | Stock Option (Right to Buy) | 92000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| March 7, 2024 | C4 Therapeutics, Inc. | $CCCC | Schick Kelly | Chief People Officer | A | Stock Option (Right to Buy) | 92000 | $0.00 | 92,000.0000 | 0 | 9999.99% | 0.00% |
| March 7, 2024 | C4 Therapeutics, Inc. | $CCCC | Schick Kelly | Chief People Officer | D | Stock Option (Right to Buy) | 78500 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| March 7, 2024 | C4 Therapeutics, Inc. | $CCCC | Schick Kelly | Chief People Officer | A | Stock Option (Right to Buy) | 78500 | $0.00 | 78,500.0000 | 0 | 9999.99% | 0.00% |
| Feb. 14, 2024 | C4 Therapeutics, Inc. | $CCCC | Schick Kelly | Chief People Officer | A | Stock Option (Right to Buy) | 122800 | $0.00 | 122,800.0000 | 0 | 9999.99% | 0.00% |
| Feb. 13, 2024 | C4 Therapeutics, Inc. | $CCCC | Schick Kelly | Chief People Officer | F | Common Stock | 1735 | $6.53 | 24,951.0000 | 0 | 6.50% | 0.00% |
| Feb. 14, 2024 | C4 Therapeutics, Inc. | $CCCC | Schick Kelly | Chief People Officer | A | Common Stock | 27300 | $0.00 | 52,251.0000 | 0 | 109.41% | 0.00% |